Takeda Pharmaceutical Company Limited (TKPHF)
OTC PINK OTC PINK Primary Summary
TKPHF Chart
Takeda Pharmaceutical Company Limited Dividends
| TKPHF In 8 months | Other | $0.69 Per Share |
| TKPHF In 2 months | Other | $0.69 Per Share |
| TKPHF 3 months ago Paid | Other | $0.63 Per Share |
| TKPHF 9 months ago Paid | Other | $0.63 Per Share |
| TKPHF 9 months ago | Other | $0.68 Per Share |
Takeda Pharmaceutical Company Limited Earnings
| 30 Jul 2025 (In 3 weeks) Date | | 40.4 Cons. EPS | - EPS |
| 29 Jul 2025 (In 2 weeks) Date | | - Cons. EPS | - EPS |
| 7 May 2025 Date | | - Cons. EPS | - EPS |
| 30 Jan 2025 Date | | 0.1 Cons. EPS | 0.1 EPS |
| 31 Oct 2024 Date | | 15.85 Cons. EPS | 58.14 EPS |
| TKPHF In 8 months | Other | $0.69 Per Share |
| TKPHF In 2 months | Other | $0.69 Per Share |
| TKPHF 3 months ago Paid | Other | $0.63 Per Share |
| TKPHF 9 months ago Paid | Other | $0.63 Per Share |
| TKPHF 9 months ago | Other | $0.68 Per Share |
| 30 Jul 2025 (In 3 weeks) Date | | 40.4 Cons. EPS | - EPS |
| 29 Jul 2025 (In 2 weeks) Date | | - Cons. EPS | - EPS |
| 7 May 2025 Date | | - Cons. EPS | - EPS |
| 30 Jan 2025 Date | | 0.1 Cons. EPS | 0.1 EPS |
| 31 Oct 2024 Date | | 15.85 Cons. EPS | 58.14 EPS |
Takeda Pharmaceutical Company Limited (TKPHF) FAQ
What is the stock price today?
On which exchange is it traded?
What is its stock symbol?
Does it pay dividends? What is the current yield?
What is its market cap?
When is the next earnings date?
Has Takeda Pharmaceutical Company Limited ever had a stock split?
Takeda Pharmaceutical Company Limited Profile
| Drug Manufacturers - Specialty & Generic Industry | Healthcare Sector | Mr. Christophe Weber CEO | OTC PINK Exchange | JP3463000004 ISIN |
| JP Country | 49,281 Employees | 31 Mar 2026 Last Dividend | - Last Split | - IPO Date |
Overview
Takeda Pharmaceutical Company Limited is a global leader in the pharmaceutical industry, with core research, development, manufacturing, marketing, and out-licensing activities extending across several key therapeutic areas. Founded in 1781, with its headquarters in Tokyo, Japan, Takeda has evolved into a company with a broad international presence, offering innovative solutions and treatments in gastroenterology, rare diseases, plasma-derived therapies, immunology, oncology, and neuroscience. Takeda's strategic approach includes in-license agreements and collaborations with various biotechnology and pharmaceutical companies, research institutions, and universities worldwide, aiming to deliver transformative treatments and access to innovative therapies for patients globally.
Products and Services
- Entyvio, Gattex/Revestive, Takecab/Vocinti, and more in Gastroenterology: Takeda offers a range of products targeting gastrointestinal disorders, providing innovative therapies for patients suffering from challenging conditions.
- Rare Diseases Therapies (Elaprase, Replagal, etc.): The company is committed to addressing the needs of patients with rare and complex diseases, offering specialized treatments and continuing research for new solutions.
- Plasma Derived Therapies (Adynovate/Adynovi, Feiba, etc.): Takeda excels in providing plasma-derived therapies, essential for treating rare blood disorders and other conditions, solidifying its position as a leader in this specialized field.
- Immunology (Hyqvia, Cuvitru, etc.): With products designed to modulate the immune system, Takeda supports patients with immunological disorders, facilitating improved health and well-being.
- Oncology (Ninlaro, Velcade, Adcetris, etc.): Takeda's oncology portfolio addresses various cancer types, offering hope and advanced treatment options to patients battling cancer.
- Neuroscience (Vyvanse/Elvanse, Trintellix, etc.): Reflecting its dedication to addressing neurological and psychiatric disorders, Takeda provides vital medications for ADHD, depression, and other conditions.
Besides its comprehensive product offerings, Takeda engages in numerous collaborations and licensing agreements. These partnerships span across biotech and pharmaceutical industries, including alliances with BioMarin, Luxna Biotech, GlaxoSmithKline, Neurocrine Biosciences, Seagen, Anima Biotech, and many others, underlining Takeda's commitment to fostering innovation and expanding its therapeutic impact across the globe.
Contact Information
